Ranbaxy Laboratories has put in its bid to acquire the generic business of German pharmaceutical firm Merck.Industry sources said the company had put its bid yesterday for acquiring Merck KGaA's generic business, which is estimated to be valued around $6 billion.The Gurgaon-based company has appointed Goldman Sachs and Citigroup as its managers for the deal, sources said.Merck is the fourth biggest generic drug manufacturer in the world, and Novartis AG, Stada Arzneimittel AG and Teva are reportedly to be in the race.The German company is hiving of its generic unit to concentrate on branded formulations.
